New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 7, 2012
15:10 EDTLCILannett announces renewal of universal shelf registration statement
Lannett announced that the renewal of its universal shelf registration statement on Form S-3 was declared effective by the SEC. The universal shelf registration statement replaces the company's previous shelf registration statement, which expired on November 20. The universal shelf registration statement permits the company to offer and sell, from time to time, on a continuous or delayed basis in the future, up to $63.75M of equity, debt or other types of securities described in the shelf registration statement, or any combination of such securities, in one or more future public offerings. The shelf registration statement also allowscertain shareholders to sell up to $57.5M of the company's common stock. The company will not receive any proceeds from the sale of these shares. The company's prior shelf registration statement permitted the company to offer up to $80M of securities and permitted certain shareholders to sell up to $70M of the company's common stock. The new shelf registration statement represents the unsold portion of the securities registered pursuant to the prior shelf registration statement.
News For LCI From The Last 14 Days
Check below for free stories on LCI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
13:23 EDTLCIHigh option volume stocks: RFMD LCI MR PII DG CTRL
Subscribe for More Information
10:31 EDTLCIHigh option volume stocks:
July 18, 2014
07:56 EDTLCILannett signs agreement with Symplmed
Lannett announced that it has signed an agreement with Symplmed to be the exclusive distributor in the U.S. of an authorized generic version of ACEON in 2 mg, 4 mg and 8 mg dosage strengths. According to IMS, annual total sales of Perindopril Erbumine Tablets, 2 mg, 4 mg and 8 mg, at Average Wholesale Price were approximately $3.5M. The company expects to commence shipping the product shortly.
July 17, 2014
08:56 EDTLCILannett decline on Connecticut probe seems overdone, says Roth Capital
After Lannett fell 17% following the disclosure that it had received subpoenas from Connecticut regarding the pricing of digoxin, Roth Capital does not expect the state to take any further action against the company. The firm does not believe that there has been any collusion on digoxin prices. It keeps a $45 price target and Buy rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use